Cargando…

The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis

In human gliomas, anti-tumor T cell responses are inhibited through induction of local and systemic immunosuppression. Immune checkpoint blockade is proving to be a success in several types of cancers. However, many studies reported that the treatment of glioblastoma patients with anti-CTLA-4 or ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghouzlani, Amina, Lakhdar, Abdelhakim, Rafii, Soumaya, Karkouri, Mehdi, Badou, Abdallah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563991/ https://www.ncbi.nlm.nih.gov/pubmed/34728682 http://dx.doi.org/10.1038/s41598-021-00835-0

Ejemplares similares

The Promising IgSF11 Immune Checkpoint Is Highly Expressed in Advanced Human Gliomas and Associates to Poor Prognosis
por: Ghouzlani, Amina, et al.
Publicado: (2021)

The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma
por: Issam Salah, Nour el Imane, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Human Glioma Microenvironment
por: Ghouzlani, Amina, et al.
Publicado: (2021)

NR2F6, a new immune checkpoint that acts as a potential biomarker of immunosuppression and contributes to poor clinical outcome in human glioma
por: Miftah, Hayat, et al.
Publicado: (2023)

A(2A)R as a Prognostic Marker and a Potential Immunotherapy Target in Human Glioma
por: Rafii, Soumaya, et al.
Publicado: (2023)

Deciphering immune microenvironment and cell evasion mechanisms in human gliomas
por: Rafii, Soumaya, et al.
Publicado: (2023)

TMIGD2 as a potential therapeutic target in glioma patients
por: Boulhen, Chaimae, et al.
Publicado: (2023)

High VISTA expression is linked to a potent epithelial-mesenchymal transition and is positively correlated with PD1 in breast cancer
por: Rezouki, Ibtissam, et al.
Publicado: (2023)

CAR T-cells for colorectal cancer immunotherapy: Ready to go?
por: Ghazi, Bouchra, et al.
Publicado: (2022)

The immune checkpoint adenosine 2A receptor is associated with aggressive clinical outcomes and reflects an immunosuppressive tumor microenvironment in human breast cancer
por: Zohair, Basma, et al.
Publicado: (2023)

BTN3A: A Promising Immune Checkpoint for Cancer Prognosis and Treatment
por: Kone, Abdou-samad, et al.
Publicado: (2022)

Exploring the VISTA of microglia: immune checkpoints in CNS inflammation
por: Borggrewe, Malte, et al.
Publicado: (2020)

Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer
por: Hou, Zelin, et al.
Publicado: (2020)

Immune-checkpoint protein VISTA in allergic, autoimmune disease and transplant rejection
por: Zheng, Meijun, et al.
Publicado: (2023)

Glioblastoma Following Treated Medulloblastoma After 29 Years in the Posterior Fossa: Case Report and Review of Literature
por: Mesbahi, Tarek, et al.
Publicado: (2022)

Identification of active small-molecule modulators targeting the novel immune checkpoint VISTA
por: Li, Ting-ting, et al.
Publicado: (2021)

IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy
por: Tang, Xi-Yang, et al.
Publicado: (2022)

Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights
por: Noelle, Randolph J., et al.
Publicado: (2023)

VISTA is associated with immune infiltration and predicts favorable prognosis in TNBC
por: Zhang, Mi, et al.
Publicado: (2022)

The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer
por: Xie, Xiaoxue, et al.
Publicado: (2020)

The expression of VISTA on CD4(+) T cells is associated with poor prognosis and immune status in non-small cell lung cancer patients
por: Ma, Shengyao, et al.
Publicado: (2022)

LILRB3 suppresses immunity in glioma and is associated with poor prognosis
por: Zhuang, Qiyuan, et al.
Publicado: (2023)

Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis
por: Li, Na, et al.
Publicado: (2017)

Immune checkpoint receptor VISTA on immune cells is associated with expression of T-cell exhaustion marker TOX and worse prognosis in renal cell carcinoma with venous tumor thrombus
por: Zapała, Łukasz, et al.
Publicado: (2022)

Predictive value of PIMREG in the prognosis and response to immune checkpoint blockade of glioma patients
por: Zhu, Hua, et al.
Publicado: (2022)

PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas
por: Zhang, Hao, et al.
Publicado: (2021)

TREM2 is associated with tumor immunity and implies poor prognosis in glioma
por: Yu, Mingchen, et al.
Publicado: (2023)

Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis
por: Zhou, Quanwei, et al.
Publicado: (2020)

Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA
por: Pan, Jing, et al.
Publicado: (2021)

A New VISTA on combination therapy for negative checkpoint regulator blockade
por: Deng, Jie, et al.
Publicado: (2016)

VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma
por: He, Hai-Xia, et al.
Publicado: (2021)

High Level of METTL7B Indicates Poor Prognosis of Patients and Is Related to Immunity in Glioma
por: Xiong, Yujia, et al.
Publicado: (2021)

An immune signature to predict the prognosis of ATRX-wildtype glioma patients and guide immune checkpoint blockade therapy
por: Cao, Wenpeng, et al.
Publicado: (2023)

Targeting immune checkpoints in malignant glioma
por: Zhang, Xuhao, et al.
Publicado: (2016)

Author Correction: Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis
por: Li, Na, et al.
Publicado: (2018)

Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma
por: Popp, Felix C., et al.
Publicado: (2021)

M351‐0056 is a novel low MW compound modulating the actions of the immune‐checkpoint protein VISTA
por: Hu, Xinlei, et al.
Publicado: (2021)

CASP6 predicts poor prognosis in glioma and correlates with tumor immune microenvironment
por: Guo, Kai, et al.
Publicado: (2022)

Upregulated Immunogenic Cell-Death-Associated Gene Signature Predicts Reduced Responsiveness to Immune-Checkpoint-Blockade Therapy and Poor Prognosis in High-Grade Gliomas
por: Tang, Xin, et al.
Publicado: (2022)

Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy
por: Yokohama, Keisuke, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_81n2ee2aghohijguk764bhausa